Antitumoral effects of the vitamin D analogue EM1 on glioblastoma multiforme cell lines.

FERRONATO M.J.; ALONSO E.N.; FERMENTO M.E.; OBIOL D.J.; GANDINI N.A.; QUEVEDO M.A.; LOPEZ ROMERO A.; MASCARÓ E.; VITALE C.; FACCHINETTI M.M.; CURINO A. C.

Mar del Plata

Congreso; LXI Reunión Anual de la Sociedad Argentina de Investigaciones Clínicas (SAIC); 2016

Sociedad Argentina de Investigación Clínica (SAIC)

Currently, first-line adjuvant treatment for glioblastoma is based on the combination of radiotherapy and temozolomide. Although the combination treatment has slightly improved patient survival, novel strategies aimed at prolonging the survival and ensuring a better quality of life are necessary. EM1 is a novel calcitriol analogue with antitumoral properties and, as a steroid compound, has the potential to cross the blood-brain barrier. The aim of the present study was to evaluate the potential of EM1 as a chemo-sensitizing agent in glioblastoma treatment by investigating its antitumoral effects on human T98G and U251 cells, and modeling EM1 binding to its receptor VDR by in silico assays. In culture results showed that the analogue exerts a significant decrease in T98G cell viability through cell cycle arrest in G0/G1 phase (p